We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

371:HKEXBeijing Enterprises Water Group Limited Analysis

Data as of 2026-05-20 - not real-time

NT$34.25

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Cenra Inc. is trading just below its recent resistance level, with the 20‑day SMA positioned just above the 50‑day SMA, indicating a modest upward bias. The RSI sits in the upper‑mid range, while the MACD line remains above its signal, producing a positive histogram that supports a short‑term bullish tilt. Beta is exceptionally low, suggesting minimal market‑wide price swings, yet the 30‑day volatility is elevated, reflecting a more pronounced price swing in recent weeks. Volume is on an upward trend, providing additional liquidity support for the current price action.
Fundamentally, the company posted a slight revenue contraction but maintains healthy gross and operating margins, strong operating cash flow, and a comfortable cash‑to‑debt profile. The dividend yield hovers around three percent with a payout ratio comfortably below fifty percent, indicating sustainable income potential. However, the discounted cash‑flow model places fair value well beneath the market price, and the price‑to‑earnings multiple is markedly lower than the sector average, flagging a potential overvaluation. The blend of a solid dividend, low systematic risk, and modest growth prospects positions the stock as a defensive, value‑oriented holding rather than a high‑growth play.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and RSI in supportive range
  • Price approaching near‑term resistance
  • Elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Valuation gap between market price and DCF estimate
  • Sustainable dividend yield
  • Low beta and stable cash flow

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Defensive healthcare sector positioning
  • Consistent dividend payouts
  • Limited growth outlook but strong balance sheet

Key Metrics & Analysis

Financial Health

Revenue Growth-1.20%
Profit Margin4.42%
P/E Ratio14.4
ROE4.84%
ROA2.42%
Debt/Equity38.95
P/B Ratio0.5
Op. Cash FlowNT$849.7M
Free Cash FlowNT$387.7M
Industry P/E27.2

Technical Analysis

TrendNeutral
RSI58.0
SupportNT$31.55
ResistanceNT$35.30
MA 20NT$33.29
MA 50NT$33.17
MA 200NT$33.68
MACDBullish
VolumeIncreasing
Fear & Greed Index89.46

Valuation

Fair ValueNT$19.64
GradeOvervalued
TypeValue
Dividend Yield2.99%

Risk Assessment

Beta0.13
Volatility24.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.